Armata Pharmaceuticals Competitors
| ARMP Stock | USD 9.35 0.74 8.59% |
Armata Pharmaceuticals vs Innate Pharma Correlation Details
Strong inverse diversification
Across the chosen horizon, Armata Pharmaceuticals and Innate Pharma show a correlation of -0.43 and fall into the Strong inverse diversification bucket. The overlap area shows the portion of risk that can be diversified away by holding both instruments together.
Moving against Armata Stock
Mean reversion in Armata Pharmaceuticals' price occurs when temporary dislocations correct back toward historical fair value. This tendency of Armata Pharmaceuticals' price to converge to an average value over time is called mean reversion.
Armata Pharmaceuticals Competition Correlation Matrix
Studying peer correlation around Armata Pharmaceuticals gives investors a cleaner read on how much independent price behavior still exists across the competitive set. A reading near +1 usually means prices have moved in tandem, a reading near -1 suggests opposite movement, and a reading near zero points to weaker historical dependence.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
Return momentum in Armata Stock is more useful when tested against peer-relative fundamentals and risk. Without risk-adjusted context, investors may overweight short-term returns and underweight the volatility required to achieve them. These indicators are quantitative in nature and help investors evaluate volatility and risk-adjusted expected returns across different positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| SGMO | 4.74 | 0.17 | 0.01 | 0.00 | 6.23 | 7.89 | 73.25 | |||
| IMDX | 3.82 | -0.15 | 0.00 | -0.27 | 0.00 | 8.67 | 32.12 | |||
| CCCC | 4.23 | 0.65 | 0.14 | 0.51 | 4.09 | 10.99 | 31.18 | |||
| CDXS | 4.42 | 0.32 | 0.07 | 0.82 | 4.58 | 13.61 | 41.48 | |||
| OABI | 2.21 | -0.24 | 0.00 | -0.33 | 0.00 | 4.62 | 16.11 | |||
| NVCT | 2.45 | 0.11 | 0.03 | 0.03 | 3.16 | 6.17 | 18.34 | |||
| NTHI | 3.92 | 0.27 | 0.04 | 0.05 | 4.67 | 8.43 | 24.32 | |||
| SLS | 5.57 | 1.56 | 0.24 | 1.09 | 5.69 | 15.13 | 34.72 | |||
| IPHA | 2.59 | -0.38 | 0.00 | -0.54 | 0.00 | 4.00 | 25.12 |
Peer Comparison: Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in Armata Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Armata Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Compare Armata Pharmaceuticals and related stocks such as Sangamo Therapeutics, Insight Molecular, and C4 Therapeutics Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SGMO | -308 K | -35.8 M | -22.3 M | -26.6 M | -26.4 M | -40.7 M | -71.7 M | -54.6 M | -68.3 M | -75.8 M | -121.1 M | -178.3 M | -192.3 M | -257.8 M | -97.9 M | -88.1 M | -83.7 M |
| IMDX | -3.5 M | -3.5 M | -3.5 M | -3.5 M | -5 M | -8.7 M | -11.2 M | -19.4 M | -15.8 M | -22.3 M | -29.9 M | -64.1 M | -72.9 M | -27.8 M | -60.7 M | -54.6 M | -51.9 M |
| CCCC | -15.7 M | -15.7 M | -15.7 M | -15.7 M | -15.7 M | -15.7 M | -15.7 M | -15.7 M | -15.7 M | -34.1 M | -66.3 M | -83.9 M | -128.2 M | -132.5 M | -105.3 M | -105 M | -110.2 M |
| CDXS | -18.7 M | -16.6 M | -30.9 M | -41.3 M | -19.1 M | -7.6 M | -8.6 M | -23 M | -10.9 M | -11.9 M | -24 M | -21.3 M | -33.6 M | -76.2 M | -65.3 M | -44 M | -46.2 M |
| OABI | -13.6 M | -13.6 M | -13.6 M | -13.6 M | -13.6 M | -13.6 M | -13.6 M | -13.6 M | -13.6 M | -13.6 M | -17.6 M | -27 M | -22.3 M | -50.6 M | -62 M | -64.8 M | -61.5 M |
| NVCT | -10 K | -10 K | -10 K | -10 K | -10 K | -10 K | -10 K | -10 K | -10 K | -10 K | -10 K | -12.9 M | -18.8 M | -22.3 M | -19 M | -26.4 M | -27.8 M |
| NTHI | -3.4 M | -3.4 M | -3.4 M | -3.4 M | -3.4 M | -3.4 M | -3.4 M | -3.4 M | -3.4 M | -3.4 M | -3.4 M | -3.4 M | -3 M | -14.9 M | -11.9 M | -10.7 M | -11.2 M |
| SLS | -2.4 M | -11.5 M | -35 M | -76.7 M | -36.6 M | -63.9 M | -23.5 M | -23.8 M | -27.7 M | -19.3 M | -16.8 M | -20.7 M | -41.3 M | -37.3 M | -30.9 M | -26.9 M | -28.2 M |
| IPHA | -6.1 M | -7 M | -3.2 M | -2.9 M | -19.6 M | -6.7 M | 12.6 M | -48.4 M | 3 M | -20.8 M | -64 M | -52.8 M | -58.1 M | -7.6 M | -49.5 M | -44.5 M | -42.3 M |
Armata Pharmaceuticals Competitive Analysis
Armata Pharmaceuticals competes directly with Sangamo Therapeutics, Insight Molecular, and C4 Therapeutics, and the financial data points to clear areas of divergence. On scale alone, Armata Pharmaceuticals' 298.9 M valuation and 5.1 M revenue define its weight class. Armata Pharmaceuticals posts a -3439.35% return on equity, reflecting current earnings headwinds. Top-line revenue favors Sangamo Therapeutics by a wide margin: 57.8 M to 5.1 M. Armata Pharmaceuticals leads with -3439.35% return on equity versus -23603.11% for Insight Molecular. On pure scale, Armata Pharmaceuticals is the larger business with market caps of 298.9 M versus 243.9 M.| Better Than Average | Worse Than Peers | View Performance Chart |
Armata Pharmaceuticals Competition Peer Performance Charts
How to Analyze Armata Pharmaceuticals Against Peers
Armata Pharmaceuticals' peer analysis compares Armata Pharmaceuticals with related companies to put valuation, quality, and risk metrics in context. This helps determine whether recent performance is company-specific or broadly sector-driven. A practical workflow includes:- Set a relevant peer group: Include direct competitors and close alternatives with comparable business exposure.
- Benchmark core financials: Compare profitability, growth, capital structure, and cash flow quality.
- Check valuation dispersion: Review whether Armata Pharmaceuticals trades at a premium or discount versus peers and why.
- Evaluate risk profile: Compare volatility, drawdowns, and correlation to avoid false diversification assumptions.
- Document the thesis: Record where Armata Pharmaceuticals leads or lags and what catalysts could close or widen the gap.
Peer Comparison Metrics & Methodology
Operating expenses at Armata Pharmaceuticals as a share of revenue sit below the peer group midpoint, signaling tighter cost control. Relative ranking may help frame which fundamentals deserve deeper follow-up. For peer comparison, Armata Pharmaceuticals has a market cap of 298.9 M.
Unless otherwise specified, data for Armata Pharmaceuticals is compiled from periodic company reporting and market reference feeds and standardized for comparability. Professional analyst research is incorporated when coverage is available. Updates may occur throughout the day.